Immunoprecipitation (IP) is a small-scale affinity purification technique used to isolate and concentrate a particular antigen from a sample solution, which may contain numerous other proteins. This is achieved by using an antibody that recognizes the target protein and is immobilized to a solid support like magnetic particles or agarose resin.
There are several different approaches, including the traditional (classical) method, oriented affinity method and direct affinity method. The traditional method of IP involves incubating the antibody with a sample, then binding it to Protein A or G agarose. However, this can lead to the target protein getting contaminated with the IP antibody, complicating subsequent analyses.
The oriented affinity technique uses Protein A or G beads as anchors, crosslinking the IP antibody to them. This prevents the antibody and target protein from being eluted together. In another approach, the direct affinity method attaches the IP antibody directly to a chemically activated base.1
IP offers several benefits for scientists, such as detecting protein activation states, post-translational modifications, estimating molecular weights of proteins, and investigating protein-protein and protein-nucleic acid interactions.
At Biointron, we are dedicated to accelerating your antibody discovery, optimization, and production needs. Our team of experts can provide customized solutions that meet your specific research needs. Contact us to learn more about our services and how we can help accelerate your research and drug development projects.
References:
Kaboord, B., & Perr, M. (2008). Isolation of proteins and protein complexes by immunoprecipitation. Methods in molecular biology (Clifton, N.J.), 424, 349–364. https://doi.org/10.1007/978-1-60327-064-9_27
Biointron’s AbDrop & Cyagen’s HUGO-Ab is a high-throughput fully human antibody discovery platform that combines microdroplet-based single B cell screening with transgenic mice. This combination accelerates the discovery and development of fully human antibodies, reducing the time from target identification to therapeutic candidate to just three months.
The development of chimeric antibodies was a significant turning point in antibody engineering. To engineer more human-like antibodies, researchers combined the variable regions of antibodies from one species with the constant regions of another, resulting in increased antigen specificity with reduced immunogenicity. This was a key advance in making antibodies more suitable for therapeutic applications in humans.
DOI:10.1016/j.trecan.2024.07.002Bispecific antibodies (bsAbs) are a class of engineered therapeutic molecules designed to engage two different epitopes or antigens simultaneously, providing them with unique functionalities that go beyond traditional monoclonal antibodies. By targeting two distinct a
The 22nd Annual Discovery on Target 2024 was held in Boston, MA on September 30 to October 3, 2024. This four-day event involved discussion on popular topics like kinases, immunomodulation, and degraders, plus coverage of covalent chemistries and induced proximity, synthetic biology, cancer antibodies, generative AI, and translational models.
